Sanofi's Sarclisa (isatuximab-irfc) Receives the US FDA's Approval for Relapsed Refractory Multiple Myeloma
Shots:
- The approval is based on P-III ICARIA-MM study Sarclisa (IV- 10mg/kg) + pomalidomide + dexamethasone (pom-dex) vs pom-dex as monothx. in patients with RRMM- prior treated with at least two therapies including lenalidomide and a proteasome inhibitor
- The P-III ICARIA-MM study results: improvement in PFS (11.53 vs 6.47); improvement in ORR (60.4% vs 35.3%)
- Sarclisa is mAb targeting CD38 receptor on MM cells- act by inducing apoptosis & immunomodulatory activity and has received FDA & EMA’s ODD with its anticipated availability in the US soon
Click here to read full press release/ article | Ref: Sanofi | Image: Pinterest
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com